drugset / Trial / NCT06716307

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

NCT06716307

Phase 1 Completed 18 enrolled Novo Nordisk A/S
RandomizedCrossoverOpen-labelTreatment

Summary

This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide. It is still being tested in studies and is not yet available for doctors to prescribe. Participants will get an injection with each of the two versions of CagriSema at two different times at the clinic. Like all medicines, the study medicine may have side effects. The study will last for about 18 weeks.

Timeline

Start
2024-12-02
Primary completion
2025-03-28
Completion
2025-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Cagrilintide Protein / enzyme biologic Subcutaneous
Subject Semaglutide Peptide Subcutaneous

Indications